Month: April 2025

AKVA Group ASA (AKVA) is pleased to invite investors, analysts, media and other stakeholders to our Capital Markets Day (CMD) on Wednesday, June 12, 2025. The CMD will be hosted at our headquarters in Klepp, Norway, and will provide a comprehensive update on AKVA Group’s strategic roadmap, financial ambitions, and cutting-edge technological solutions across our Sea Based, Land Based, and Digital business segments. The event will feature presentations by the company’s executive management and key operational leaders. Agenda (CEST): 11:00 – Arrival and networking lunch 12:00 – 15:00 – CMD presentations followed by Q&A sessions 15:00 – 17:00 – Site-visit and product demonstrations 17:00 – 17:30 – Refreshments 17:30 – Dinner Presenters: Knut Nesse, CEO Ronny Meinkøhn, CFO Johan Fredrik Gjesdal, COO Land Based Kristian Botnen,...

VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces its subsidiary ZenaDrone has received approval from the Federal Aviation Administration (FAA) to conduct commercial agricultural operations under the rules and regulations of 14 CFR Part 137 for crop spraying and precision agriculture. This approval allows ZenaDrone to commence final testing and deployment of the ZenaDrone 1000 drone for aerial spraying of pesticides, herbicides, fungicides, fertilizers, and seeds for agricultural, environmental and government customers. The company plans to sell these solutions through its Drone as...

NORCROSS, Ga., April 24, 2025 (GLOBE NEWSWIRE) — CoreCard Corporation (NYSE: CCRD), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, intends to hold an investor conference call on May 8, 2025, at 11:00 A.M. Eastern Time in conjunction with the company’s earnings release for the quarter ended March 31, 2025. The company plans to issue a press release with the financial results for the period before the market opens on May 8, 2025. Interested investors are invited to attend the conference call by accessing the webcast at https://www.webcast-eqs.com/register/corecardq12025/en or by dialing 1-877-407-0890. As part of the conference call CoreCard will be conducting a question-and-answer session where participants are invited to email their questions...

New branding and upgraded e-commerce experience sets the stage for growth Launch of three new products and a reformulated best-seller to support brain health, hydration and emotional well-beingTORONTO, April 24, 2025 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSX.V: LFST; FRANKFURT: M5B0; OTCMKTS: LFSWF), a leading health and wellness company focused on acquiring, integrating, and building top wellness brands, announces the relaunch of its Mikra brand with a bold new e-commerce website, refreshed new branding, and a digital strategy designed to accelerate revenue generation. The revamped Mikra website – featuring baseball legend and collaborator Jose Bautista – marks a significant step in Lifeist’s execution of its 2025 strategic roadmap. Jose’s signature product lines, Clarity and Focus, are front...

LOWELL, Mass., April 24, 2025 (GLOBE NEWSWIRE) — MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI) plans to announce financial results for its second quarter ended April 4, 2025, before market open on Thursday, May 8, 2025. In conjunction with the release, MACOM will conduct a conference call at 8:30 a.m. Eastern Time on Thursday, May 8, 2025, hosted by Mr. Stephen G. Daly, President and Chief Executive Officer, and Mr. John F. Kober, Senior Vice President and Chief Financial Officer. Please visit MACOM’s Investor Relations Website to register for a user-specific access code for the live call or to access the live webcast. A replay of the call will be available within 24 hours and remain accessible by all interested parties for approximately 90 days. About MACOM MACOM designs and manufactures high-performance semiconductor...

SAN FRANCISCO, April 24, 2025 (GLOBE NEWSWIRE) — Serve Robotics Inc. (“Serve”) (Nasdaq: SERV), a leading autonomous sidewalk delivery company, today announced that it will report its 2025 first quarter financial results on Thursday, May 8, 2025 after market close. The company will host a conference call and webcast to review the results on the same day. Conference Call and Webcast InformationCompany management will host a conference call at 2 p.m. PT / 5 p.m. ET. A live audio webcast will be available at investors.serverobotics.com and a replay will be available at the same location. Analysts and investors who wish to submit questions to management may send an email to investor.relations@serverobotics.com by close of business on Wednesday, May 7, 2025. If you wish to receive company email notifications, please register at https://investors.serverobotics.com/ir-resources/email-alerts About...

TROY, Mich., April 24, 2025 (GLOBE NEWSWIRE) — Kelly, a leading global specialty talent solutions provider, will release its first-quarter earnings before the market opens on Thursday, May 8, 2025. In conjunction with its earnings release, Kelly will publish a financial presentation and host a live webcast of a conference call with financial analysts at 9 a.m. ET on May 8 to review the results from the quarter and answer questions. The presentation and a link to the live webcast will be accessible through the Company’s public website on the Investor Relations page under Events & Presentations. The webcast will be recorded, and a replay will be available within one hour of completion of the event through the same link as the live webcast. About Kelly Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage...

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com. About...

MIAMI, April 24, 2025 (GLOBE NEWSWIRE) — Global Crossing Airlines Group, Inc. (Cboe CA: JET, Cboe CA: JET.B, OTCQB: JETMF) (the “Company” or “GlobalX”), the Nation’s fastest growing charter airline, will host a conference call on Thursday, May 8, 2025 at 8:30 a.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2025. The Company’s results will be reported in a press release prior to the call. GlobalX’s management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing JET@elevate-ir.com. Date: Thursday, May 8, 2025Time: 8:30 a.m. Eastern timeToll-free dial-in number: (800) 717-1738 International dial-in number: (646) 307-1865Conference ID: 10283Webcast: GlobalX’s Q1 2025 Conference...

– Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months – – Data from the fully enrolled DELIVER registrational expansion cohort is planned for late 2025 – WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that the European Commission (EC) has granted orphan drug designation for DYNE-251 for the treatment of Duchenne muscular dystrophy (DMD). DYNE-251 is being evaluated in the Phase 1/2 DELIVER global clinical trial in individuals with DMD who are amenable to exon 51 skipping. Long-term clinical data from the ongoing DELIVER trial of DYNE-251 that demonstrated...